Company
NILO Therapeutics
Harnessing neural circuits to restore immune homeostasis in disease
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
By targeting master regulator brain-body circuits that centrally control systemic inflammation, Nilo is pioneering a differentiated approach to immunomodulation with the potential to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet need.
Funding snapshot
- Total raised
- $101MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $101M2025-10-08
Funding rounds
- Series A
- $101M2025-10-08, Company stated
Loading relationship preview